[to top of second column]
And she'll buy a new prosthetic. She might even get her car adapted so she doesn't have to use her left hand to reach across the steering column to reach the ignition.
"It's very good for her spirit," said daughter Jassamine Levine, 26. "Both of our spirits were wibbling and wobbling, like `How can this be possible, that a company could value money and power over what's right?' It's pretty unfathomable.
"But the fact that the justice system worked, it's pretty impressive," said the daughter.
Wyeth is in the process of being bought by rival Pfizer Inc. in a $68 billion deal that is expected to close later this year.
Wyeth said it was disappointed by the ruling.
"When lay juries are permitted to second-guess the experts at FDA on the benefits and risks of particular medicines, the result is uncertainty for patients and doctors alike about how and when to use prescription drugs," the Madison, N.J.-based company said in a statement.
Drug industry analysts say the ruling will force makers to scrutinize safety issues of all experimental drugs in development, as well as existing products.
"They will weigh how prevalent the side effect is, how serious the side effect is, versus the number of people benefiting from the drug and the amount of money being made by the drug," said Erik Gordon, an analyst and professor at University of Michigan's Ross School of Business.
"This is like blood in the water for plaintiff lawyer sharks," and will encourage more lawsuits, Gordon added.
Levine says she would happily trade the money for her arm, if she could.
"I miss my arm. I really miss my arm. I grieve the loss of my arm, nine years later. I would give $6 million for my right arm," she said.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor